$CUE
Cue Biopharma Inc Stock $cue

$cue Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-K Financial Statement

#000156459021011777 Filed on March 09, 2021

Income Statement

Concept	2019 Q4	2019	2018 Q4
Revenue	$1.050M	$3.458M	$330.0K
YoY Change	218.18%	202.67%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.100M	$12.68M	$4.460M
YoY Change	-30.49%	12.61%	216.31%
% of Gross Profit
Research & Development	$6.900M	$27.49M	$6.630M
YoY Change	4.07%	-3.7%	-25.51%
% of Gross Profit
Depreciation & Amortization	$200.0K	$799.1K	$200.0K
YoY Change	0.0%	5.15%	53.85%
% of Gross Profit
Operating Expenses	$10.06M	$40.23M	$11.30M
YoY Change	-10.97%	0.97%	8.24%
Operating Profit
YoY Change
Interest Expense	$110.0K	$482.8K	$100.0K
YoY Change	10.0%	28.4%
% of Operating Profit
Other Income/Expense, Net	-$10.00K	$482.8K	$70.00K
YoY Change	-114.29%	-10.82%
Pretax Income	-$8.920M	-$36.29M	-$10.80M
YoY Change	-17.41%	-4.9%	3.45%
Income Tax	$0.00	$412.5K	$830.0K
% Of Pretax Income
Net Earnings	-$8.920M	-$36.70M	-$11.62M
YoY Change	-23.24%	-5.85%	11.3%
Net Earnings / Revenue	-849.52%	-1061.18%	-3521.21%
Basic Earnings Per Share
Diluted Earnings Per Share	-$369.2K	-$1.665M	-$575.2K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q4	2019	2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$59.41M	$59.41M	$39.21M
YoY Change	51.51%	51.32%	-38.28%
Cash & Equivalents	$44.29M	$44.29M	$20.80M
Short-Term Investments	$15.12M	$15.12M	$18.41M
Other Short-Term Assets	$900.0K	$860.0K	$1.300M
YoY Change	-30.77%	-36.3%	-13.33%
Inventory
Prepaid Expenses
Receivables	$754.9K	$750.0K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$61.02M	$61.02M	$40.61M
YoY Change	50.27%	50.26%	-37.59%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.847M	$7.180M	$2.781M
YoY Change	-33.6%	158.27%	64.53%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$673.6K	$3.400M	$808.7K
YoY Change	-16.71%	72.59%	307.87%
Total Long-Term Assets	$10.58M	$10.59M	$4.753M
YoY Change	122.6%	122.95%	151.64%
TOTAL ASSETS
Total Short-Term Assets	$61.02M	$61.02M	$40.61M
Total Long-Term Assets	$10.58M	$10.59M	$4.753M
Total Assets	$71.61M	$71.61M	$45.36M
YoY Change	57.85%	57.87%	-32.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$882.7K	$880.0K	$2.035M
YoY Change	-56.63%	-56.86%	22.67%
Accrued Expenses	$2.227M	$6.410M	$1.788M
YoY Change	24.57%	333.11%	55.34%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.66M	$11.66M	$6.217M
YoY Change	87.48%	87.46%	16.28%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$5.400M	$5.370M	$5.200M
YoY Change	3.85%	3.87%
Total Long-Term Liabilities	$5.400M	$5.370M	$5.200M
YoY Change	3.85%	3.87%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.66M	$11.66M	$6.217M
Total Long-Term Liabilities	$5.400M	$5.370M	$5.200M
Total Liabilities	$17.02M	$17.02M	$11.39M
YoY Change	49.42%	49.43%	113.05%
SHAREHOLDERS EQUITY
Retained Earnings	-$108.5M		-$71.80M
YoY Change	51.11%		118.77%
Common Stock	$163.1M		$105.8M
YoY Change	54.18%		12.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$54.58M	$54.58M	$33.97M
YoY Change
Total Liabilities & Shareholders Equity	$71.61M	$71.61M	$45.36M
YoY Change	57.85%	57.87%	-32.25%

Cashflow Statement

Concept	2019 Q4	2019	2018 Q4
OPERATING ACTIVITIES
Net Income	-$8.920M	-$36.70M	-$11.62M
YoY Change	-23.24%	-5.85%	11.3%
Depreciation, Depletion And Amortization	$200.0K	$799.1K	$200.0K
YoY Change	0.0%	5.15%	53.85%
Cash From Operating Activities	-$6.440M	-$30.80M	-$3.900M
YoY Change	65.13%	16.61%	106.35%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K	$46.35K	-$120.0K
YoY Change	-91.67%	-97.5%	1100.0%
Acquisitions
YoY Change
Other Investing Activities	-$15.14M	$3.490M	$4.810M
YoY Change	-414.76%	-118.86%
Cash From Investing Activities	-$15.14M	$3.447M	$4.690M
YoY Change	-422.81%	-116.93%	-47000.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		-$48.91M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	34.49M	50.79M	4.170M
YoY Change	727.1%	1114.53%	-93.28%
NET CHANGE
Cash From Operating Activities	-6.440M	-30.80M	-3.900M
Cash From Investing Activities	-15.14M	3.447M	4.690M
Cash From Financing Activities	34.49M	50.79M	4.170M
Net Change In Cash	12.91M	23.44M	4.960M
YoY Change	160.28%	-155.04%	-91.75%
FREE CASH FLOW
Cash From Operating Activities	-$6.440M	-$30.80M	-$3.900M
Capital Expenditures	-$10.00K	$46.35K	-$120.0K
Free Cash Flow	-$6.430M	-$30.84M	-$3.780M
YoY Change	70.11%	9.12%	101.06%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0175
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0243
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.880
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.820
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0258
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0295
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.940
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.836
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y1M28D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y7M20D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y6M3D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y10D
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-38327
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-3324577
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	21 Erie Street
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02139
CY2020	dei	City Area Code CityAreaCode	617
CY2020	dei	Local Phone Number LocalPhoneNumber	949-2680
CY2020	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	463914
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	74866133
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44290030
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	10002550
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	15119925
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1417482
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	754898
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1241239
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	860107
CY2020Q4	us-gaap	Assets Current AssetsCurrent	87527404
CY2019Q4	us-gaap	Assets Current AssetsCurrent	61024960
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2108024
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1846922
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6774229
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5337026
CY2020Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	2572476
CY2019Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	2572476
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	150000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	150000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	401667
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	673625
CY2020Q4	us-gaap	Assets Assets	99533800
CY2019Q4	us-gaap	Assets Assets	71605009
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2070303
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	882666
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2787211
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2227352
CY2020Q4	cue	Research And Development Contract Liability Current ResearchAndDevelopmentContractLiabilityCurrent	6681025
CY2019Q4	cue	Research And Development Contract Liability Current ResearchAndDevelopmentContractLiabilityCurrent	4097443
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4777427
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4447787
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16315966
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11655248
CY2020Q4	cue	Research And Development Contract Liability Noncurrent ResearchAndDevelopmentContractLiabilityNoncurrent	1937575
CY2019Q4	cue	Research And Development Contract Liability Noncurrent ResearchAndDevelopmentContractLiabilityNoncurrent	4017894
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2368787
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1347971
CY2020Q4	us-gaap	Liabilities Liabilities	20622328
CY2019Q4	us-gaap	Liabilities Liabilities	17021113
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30351366
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30351366
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26562178
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26562178
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	30351
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	26562
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	232159029
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	163067773
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	7131
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-10321
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-153285039
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-108500118
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	78911472
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	54583896
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	99533800
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	71605009
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3154325
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3458331
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14651205
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12740093
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27487485
CY2019	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	482790
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-44578671
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-36286457
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	206250
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	412500
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-44784921
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	17452
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	637
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-44767469
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-36698320
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.56
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.66
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28688625
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22041792
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	33971469
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	48998907
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6520982
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1881873
CY2019	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	12
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	637
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-36698957
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	56682236
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10480782
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2203061
CY2020	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	17
CY2020	us-gaap	Restricted Stock Award Forfeitures RestrictedStockAwardForfeitures	271051
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	17452
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-44784921
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	78911472
CY2020	us-gaap	Profit Loss ProfitLoss	-44784921
CY2019	us-gaap	Profit Loss ProfitLoss	-36698957
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1057458
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	810782
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	10480782
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	6520982
CY2019	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-54274
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	563232
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	83694
CY2019	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-72464
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	662584
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	754898
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	381132
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-487182
CY2020	cue	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-4202480
CY2019	cue	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	4354810
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	4971
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-123437
CY2019	cue	Increase Decrease In Deposit Liabilities IncreaseDecreaseInDepositLiabilities	-1559704
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	741265
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1152688
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	559859
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	439290
CY2020	cue	Increase Decrease In Research And Development Contract Liability IncreaseDecreaseInResearchAndDevelopmentContractLiability	503263
CY2019	cue	Increase Decrease In Research And Development Contract Liability IncreaseDecreaseInResearchAndDevelopmentContractLiability	928588
CY2020	cue	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	4678965
CY2019	cue	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-4277544
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-32494034
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30796910
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	595259
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	46353
CY2020	cue	Payments For Redemption Of Short Term Investments PaymentsForRedemptionOfShortTermInvestments	-15000000
CY2019	cue	Payments For Redemption Of Short Term Investments PaymentsForRedemptionOfShortTermInvestments	-18500000
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	9948867
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	15134324
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	127500
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4455874
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3446823
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	56682236
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	48998907
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	271051
CY2019	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	91027
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2203061
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1881873
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	50789765
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	23439678
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.48%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include estimates related to revenue, the accounting for potential liabilities and accrued expenses, the assumptions utilized in valuing stock-based compensation issued for services, the realization of deferred tax assets, and the useful life with respect to long-lived assets and intangibles. Actual results could differ from those estimates.</p>
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	44440030
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	412500
CY2020	cue	Payments To Acquire Property Plant And Equipment In Account Payable Or Accrued Expenses PaymentsToAcquirePropertyPlantAndEquipmentInAccountPayableOrAccruedExpenses	446372
CY2020	cue	Operating Lease Modification OperatingLeaseModification	5639000
CY2020	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2014-12-31
CY2020Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	84900000
CY2020	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reclassifications</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.28%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.</p>
CY2020	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P15Y
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	11666
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	11667
CY2020Q4	cue	Fair Value Assets Among Level2 And Level3 Transfers Amount FairValueAssetsAmongLevel2AndLevel3TransfersAmount	0
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	206250
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	412500
CY2019Q4	cue	Fair Value Assets Among Level2 And Level3 Transfers Amount FairValueAssetsAmongLevel2AndLevel3TransfersAmount	0
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6122870
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6049747
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	9995419
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7131
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	10002550
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	15130246
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	10321
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	15119925
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	10002550
CY2020	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	17452
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	15119925
CY2019	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	637
CY2020Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	72943275
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	10002550
CY2019Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	39303609
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	15119925
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	485105
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	550063
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4793253
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	755725
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4540321
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.08
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1288100
CY2019	us-gaap	Depreciation Depreciation	799114
CY2019	cue	Amortization Of Trademark AmortizationOfTrademark	11667
CY2020	us-gaap	Depreciation Depreciation	780529
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4914603
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3872972
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2806579
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2026050
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2108024
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1846922
CY2020	cue	Amortization Of Trademark AmortizationOfTrademark	11666
CY2020	cue	Amortization Of Capitalized License Expense AmortizationOfCapitalizedLicenseExpense	265263
CY2020Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1963983
CY2019Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1575821
CY2020Q4	cue	Accrued Contract Manufacturing Services Current AccruedContractManufacturingServicesCurrent	108880
CY2019Q4	cue	Accrued Contract Manufacturing Services Current AccruedContractManufacturingServicesCurrent	150250
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	326028
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	383910
CY2020Q4	cue	Accrued Contract Research Services Current AccruedContractResearchServicesCurrent	388320
CY2019Q4	cue	Accrued Contract Research Services Current AccruedContractResearchServicesCurrent	117371
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2787211
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2227352
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.10
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	981800
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	17.31
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	454497
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.86
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	289657
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	10.14
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5030899
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.10
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2920318
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.05
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	15605021
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	16869399
CY2020Q4	cue	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Of Options Exercisable Intrinsic Fair Value Per Share ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsExercisableIntrinsicFairValuePerShare	7.05
CY2020	cue	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Of Options Market Close Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsMarketClosePrice	12.51
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.05
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y10D
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	19471155
CY2019Q4	cue	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Of Options Exercisable Intrinsic Fair Value Per Share ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsExercisableIntrinsicFairValuePerShare	6.26
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	94375
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	7.83
CY2020Q1	cue	Share Based Compensation Arrangement By Share Based Payment Award Post Employment Options Exercise Period ShareBasedCompensationArrangementByShareBasedPaymentAwardPostEmploymentOptionsExercisePeriod	P12M
CY2020Q2	cue	Share Based Compensation Arrangement By Share Based Payment Award Post Employment Options Exercise Period ShareBasedCompensationArrangementByShareBasedPaymentAwardPostEmploymentOptionsExercisePeriod	P36M
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1189827
CY2020	cue	Class Of Warrants Or Rights Cashless Issue Exercises ClassOfWarrantsOrRightsCashlessIssueExercises	278179
CY2020	cue	Class Of Warrant Or Right Number Of Securities Withheld ClassOfWarrantOrRightNumberOfSecuritiesWithheld	49679
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	861969
CY2020Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	2500000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30351366
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30351366
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26562178
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26562178
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	206250
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	34539000
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	23348000
CY2020Q4	cue	Deferred Tax Assets Tax Credit Carryforwards Research And Other DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther	2312000
CY2019Q4	cue	Deferred Tax Assets Tax Credit Carryforwards Research And Other DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther	2069000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	7446000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	5281000
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	44297000
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	30701000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	42321000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	29095000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1976000
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1606000
CY2020Q4	cue	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	1974000
CY2019Q4	cue	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	1606000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	-2000
CY2020	cue	Deferred Tax Assets Valuation Allowance Percentage DeferredTaxAssetsValuationAllowancePercentage	1
CY2019	cue	Deferred Tax Assets Valuation Allowance Percentage DeferredTaxAssetsValuationAllowancePercentage	1
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.07
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.06
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.30
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.27
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.01
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.02
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.02
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.01
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2020	cue	Effective Income Tax Rate Reconciliation Foreign Withholding Taxes EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxes	0
CY2019	cue	Effective Income Tax Rate Reconciliation Foreign Withholding Taxes EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxes	0.01
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.01
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.01
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.01
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	81000
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	13000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1675000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1334000
CY2018Q2	us-gaap	Description Of Lessee Leasing Arrangements Operating Leases DescriptionOfLesseeLeasingArrangementsOperatingLeases	Upon execution of this lease agreement the Company prepaid three months of rent, two of which will be held in escrow and credited against future rent payments and that the other of which was applied to the first months’ rent. The Company also prepaid seven and one half months’ rent pursuant to an amendment to the lease agreement executed on June 18, 2018. These amounts were recorded to deposits and prepaid expenses, respectively, at December 31, 2020
CY2018	cue	Additional Description Of Lessee Leasing Arrangements Operating Leases AdditionalDescriptionOfLesseeLeasingArrangementsOperatingLeases	The monthly rental rate under the Additional Laboratory Lease was $72,600 for the first 12 months and $78,600 for the remainder of the term. Upon execution of this lease agreement the Company prepaid 12 months’ rent pursuant to the lease agreement executed on September 20, 2018.
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1334000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	972000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	341000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	294000
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	5079642
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	2407692
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	7487334
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	341121
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	7146213
CY2020	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4593000
CY2019	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4474000

Files In Submission

Name	View Source	Status
0001564590-21-011777-index-headers.html	Edgar Link	pending
0001564590-21-011777-index.html	Edgar Link	pending
0001564590-21-011777.txt	Edgar Link	pending
0001564590-21-011777-xbrl.zip	Edgar Link	pending
cue-10k_20201231.htm	Edgar Link	pending
cue-10k_20201231_htm.xml	Edgar Link	completed
cue-20201231.xsd	Edgar Link	pending
cue-20201231_cal.xml	Edgar Link	unprocessable
cue-20201231_def.xml	Edgar Link	unprocessable
cue-20201231_lab.xml	Edgar Link	unprocessable
cue-20201231_pre.xml	Edgar Link	unprocessable
cue-ex1010_729.htm	Edgar Link	pending
cue-ex1026_791.htm	Edgar Link	pending
cue-ex1028_793.htm	Edgar Link	pending
cue-ex1030_792.htm	Edgar Link	pending
cue-ex103_736.htm	Edgar Link	pending
cue-ex104_732.htm	Edgar Link	pending
cue-ex105_733.htm	Edgar Link	pending
cue-ex106_730.htm	Edgar Link	pending
cue-ex107_735.htm	Edgar Link	pending
cue-ex108_734.htm	Edgar Link	pending
cue-ex109_731.htm	Edgar Link	pending
cue-ex21_11.htm	Edgar Link	pending
cue-ex231_15.htm	Edgar Link	pending
cue-ex311_10.htm	Edgar Link	pending
cue-ex312_9.htm	Edgar Link	pending
cue-ex321_12.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gwxbbqv42ggi000001.jpg	Edgar Link	pending
gyepu23nfprg000001.jpg	Edgar Link	pending
gyepu23nfprg000002.jpg	Edgar Link	pending
gyepu23nfprg000003.jpg	Edgar Link	pending
gyepu23nfprg000004.jpg	Edgar Link	pending
gyepu23nfprg000005.jpg	Edgar Link	pending
gyepu23nfprg000006.jpg	Edgar Link	pending
gyepu23nfprg000007.jpg	Edgar Link	pending
gyepu23nfprg000008.jpg	Edgar Link	pending
gyepu23nfprg000009.jpg	Edgar Link	pending
gyepu23nfprg000010.jpg	Edgar Link	pending
gyepu23nfprg000011.jpg	Edgar Link	pending
gyepu23nfprg000012.jpg	Edgar Link	pending
gyepu23nfprg000013.jpg	Edgar Link	pending
gyepu23nfprg000014.jpg	Edgar Link	pending
gyepu23nfprg000015.jpg	Edgar Link	pending
gyepu23nfprg000016.jpg	Edgar Link	pending
gyepu23nfprg000017.jpg	Edgar Link	pending
gyepu23nfprg000018.jpg	Edgar Link	pending
gyepu23nfprg000019.jpg	Edgar Link	pending
gyepu23nfprg000020.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CUE
Cue Biopharma Inc Stock $cue

2019 Q4 Form 10-K Financial Statement

#000156459021011777 Filed on March 09, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CUE Cue Biopharma Inc Stock $cue

2019 Q4 Form 10-K Financial Statement

#000156459021011777 Filed on March 09, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CUE
Cue Biopharma Inc Stock $cue